SEEL Seelos Therapeutics
- 0.2822
- -0.0068-2.35%
- 0.2950
- +0.0128+4.54%
Seelos Therapeutics News
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next mon
Express News | On April 30, Seelos Therapeutics Inc Announced A Reduction In Its Workforce That Affected ~33% Of Its Current Employees; Company Received Bid Notice From Nasdaq Stock Market
Seelos Therapeutics Navigates Financial and Board Changes
Express News | Seelos Therapeutics Inc - on April 30, 2024, Company Received Bid Notice From Nasdaq Stock Market LLC
Express News | Seelos Therapeutics Inc - on April 30, Announced a Reduction in Its Workforce That Affected Approximately 33% of Its Current Employees
12 Health Care Stocks Moving In Monday's After-Market Session
GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings
Express News | Seelos Therapeutics Inc - Currently in Discussions for a Potential Collaboration in Mental Health Space to Increase Shareholder Value
Express News | Seelos Therapeutics Inc - Richard Pascoe Appointed Chairman of Board of Directors
Express News | Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersXTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. The company's market cap stands at $11.0 million. Etao International Co (NASDAQ:E
Optimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Results
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersOntrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN)
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
Tuesday, Seelos Therapeutics Inc (NASDAQ:SEEL) provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. The study was designed to evaluate SLS-005 (IV trehalose), a low molecula
Express News | Seelos Therapeutics Shares Are Trading Lower After the Company Announced That Its ALS Study With SLS-005 Did Not Meet Statistical Significance in the Primary and Secondary Endpoint in the Full Analysis Set
Seelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpoints
By Chris Wack Seelos Therapeutics shares were down 47% to 48 cents in premarket trading after a Phase 2/3 trial for SLS-005 for amyotrophic lateral sclerosis failed to meet its primary endpoints. Th
Seelos Falls as Lead Drug Fails in ALS Trial
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersOntrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. The company's market cap stands at $14.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN) shares rose 97.46% t
Seelos Therapeutics Says The Study Did Not Meet Statistical Significance In The Primary And Secondary Endpoint In The Full Analysis Set
Seelos Therapeutics Says The Study Did Not Meet Statistical Significance In The Primary And Secondary Endpoint In The Full Analysis Set
Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005
Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today pro
Seelos Therapeutics Provides Update on Top-Line Results From Its Amyotrophic Lateral Sclerosis (ALS) Study With SLS-005 (IV Trehalose)
Analysis
Price Target
No Data
